Authors
- . Yahya Ali Mohzari 1
- . Ahmed Alsaegh 1
- . Syed Mohammed Basheeruddin Asdaq 2
- . Sulafah N. Al Shanawani 3
- . Amani A. Albraiki 4
- . Amal Bagalb 3
1 Department of Clinical Pharmacy, KSMC, Riyadh, Saudi Arabia
2 Department of Pharmacology, College of Pharmacy, Al-Maarefa University, Riyadh, Saudi Arabia
3 Department of Pharmaceutical Care Services, KSMC, Riyadh, Saudi Arabia
4 Department of Inpatient Pharmacies, KSMC, Riyadh, Saudi Arabia
Abstract
Objective: This study was designed to evaluate the extent of inappropriate utilization
of intravenous proton‑pump inhibitors (IV‑PPIs) and its financial burden in a Middle
Eastern tertiary care university hospital. Methods: This was an observational,
retrospective, cross-sectional study carried out in King Saud University Medical
City, Riyadh, Saudi Arabia. During a study period of 6 consecutive weeks, all
hospitalized adult patients (age ≥18) who received IV‑PPI selected and mapped
with their indications. The patient indications analyzed in comparison with the
appropriate indications developed based on the evidence from published literature
and guidelines. Findings: A total of 347 patients were identified, with a mean age
of 51.5 years, of which 51.9% were male. Of all the patients who received IV-PPIs,
251 (72.3%), 66 (19%), and 30 (8.7%) received for stress ulcer prophylaxis (SUP),
peptic ulcer disease (PUD) or gastroesophageal reflux diseases (GERDs), and upper
gastrointestinal bleeding, respectively. Overall, only 110 (31.7%) of the 347 patients
received IV-PPIs appropriately. The patients with SUP showed the highest percentage
of inappropriate use of IV-PPI (80.59%) compared to PUD/GERD (19%). The total
cost of inappropriate prescription of IV-PPI was 585,167 Saudi Riyal (SAR) (156,044
USD). Conclusion: There is a high tendency of IV-PPI’s inappropriate prescription
in our hospital setting. This large-scale inappropriate prescription of IV-PPI in the
hospital setting not only may lead to increased financial burden but also expose
patients to number of undesired effects.
Keywords
1. Yadlapati R, Kahrilas PJ. When is proton pump inhibitor use
appropriate? BMC Med 2017;15:36.
2. Friedenberg FK, Hanlon A, Vanar V, Nehemia D, Mekapati J,
Nelson DB, et al. Trends in gastroesophageal reflux disease as
measured by the National Ambulatory Medical Care Survey. Dig
Dis Sci 2010;55:1911-7.
3. Rotman SR, Bishop TF. Proton pump inhibitor use in the U.S.
ambulatory setting, 2002–2009. PloS One. 2013;8:e56060.
4. Nguyen PV, Tamaz R. Inappropriate prescription of proton
pump inhibitors in a community setting. Can J Hosp Pharm
2018;71:267-71.
5. Kelly OB, Dillane C, Patchett SE, Harewood GC, Murray FE.
The inappropriate prescription of oral proton pump inhibitors in
the hospital setting: A prospective cross-sectional study. Dig Dis
Sci 2015;60:2280-6.
6. Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors.
Pharmacology and rationale for use in gastrointestinal disorders.
Drugs 1998;56:307-35.
7. Craig DG, Thimappa R, Anand V, Sebastian S. Inappropriate
utilization of intravenous proton pump inhibitors in hospital
practice – A prospective study of the extent of the problem and
predictive factors. QJM 2010;103:327-35.
8. Lai PS, Wong YY, Low YC, Lau HL, Chin KF, Mahadeva S.
Unexplained abdominal pain as a driver for inappropriate
therapeutics: An audit on the use of intravenous proton pump
inhibitors. PeerJ 2014;2:e451.
9. Kaplan GG, Bates D, McDonald D, Panaccione R, Romagnuolo J.
Inappropriate use of intravenous pantoprazole: Extent of the
problem and successful solutions. Clin Gastroenterol Hepatol
2005;3:1207-14.
10. Pang SH, Graham DY. A clinical guide to using intravenous
proton‑pump inhibitors in reflux and peptic ulcers. Therap Adv
Gastroenterol 2010;3:11-22.
11. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis.
ASHP Commission on Therapeutics and approved by the ASHP
Board of Directors on November 14, 1998. Am J Health Syst
Pharm 1999;56:347-79.
12. Grube RR, May DB. Stress ulcer prophylaxis in hospitalized
patients not in intensive care units. Am J Health Syst Pharm
2007;64:1396-400.
13. Hoover JG, Schumaker AL, Franklin KJ. Use of intravenous
proton-pump inhibitors in a teaching hospital practice. Dig Dis
Sci 2009;54:1947-52.
14. Nalini M, Guda NM, Noonan M, Kreiner MJ, Partington S,
Vakil N. Use of intravenous proton pump inhibitors in community
practice: An explanation for the shortage. Am J Gastroenterol
2004;99:1233-7.
15. Ogasawara O, Kojima T, Miyazu M, Sobue K. Impact of the
stress ulcer prophylactic protocol on reducing the unnecessary
administration of stress ulcer medications and gastrointestinal
bleeding: A single-center, retrospective pre-post study. J Intensive
Care 2020;8:10.
16. Alsultan MS, Mayet AY, Malhani AA, Alshaikh MK. Pattern of
intravenous proton pump inhibitors use in ICU and Non-ICU
setting: A prospective observational study. Saudi J Gastroenterol
2010;16:275-9.
17. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor
therapy for peptic ulcer bleeding: Cochrane collaboration
meta-analysis of randomized controlled trials. Mayo Clin Proc
2007;82:286-96.
18. Cheung KS, Leung WK. Gastrointestinal bleeding in patients
on novel oral anticoagulants: Risk, prevention and management.
World J Gastroenterol 2017;23:1954-63.
)